Study of efficacy and safety of secukinumab in pediatric patients with severe plaque psoriasis
Phase 3
Completed
- Conditions
- Severe Chronic Pediatric Plaque Psoriasis
- Registration Number
- JPRN-jRCT2080223229
- Lead Sponsor
- ovartis Pharma K.K.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- completed
- Sex
- All
- Target Recruitment
- 5
Inclusion Criteria
*PASI score of 20 or greater at the time of randomization (Wash-out: Other systemic immunomodulating treatments: 4weeks, Phototherapy: 2weeks, Biological immunomodulating agents: 12weeks)
Exclusion Criteria
*Current forms of psoriasis other than chronic plaque-type psoriasis (for example, pustular, erythrodermic, guttate) at randomization
*Previous use of secukinumab or any drug that targets IL-17 or IL-17 receptor
Other protocol-defined inclusion/exclusion criteria may apply.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method